We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

112 hedge funds and large institutions have $656M invested in Revance Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 52 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 14

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

21% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $939K

11% more funds holding

Funds holding: 101 → 112 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $734M → $656M (-$77.3M)

Holders
112
Holders Change
+11
Holders Change %
+10.89%
% of All Funds
2.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
52
Reduced
14
Closed
9
Calls
$1.14M
Puts
$939K
Net Calls
+$197K
Net Calls Change
-$281K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$24.8M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$19M
3
BAMCO Inc
BAMCO Inc
New York
+$8.83M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$8.32M
5
Capital World Investors
Capital World Investors
California
+$7.98M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.25M
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$4.33M
3
Allianz Asset Management
Allianz Asset Management
Germany
-$1.42M
4
EAM
Erste Asset Management
Austria
-$1.3M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$2.14M +$1.83M +105,265 +344%
RHJA
27
Rice Hall James & Associates
California
$1.84M +$1.45M +83,875 +253%
Two Sigma Investments
28
Two Sigma Investments
New York
$1.84M +$2.03M +117,012 New
Principal Financial Group
29
Principal Financial Group
Iowa
$1.8M +$2.9K +167 +0.1%
Goldman Sachs
30
Goldman Sachs
New York
$1.77M +$1.27M +72,996 +185%
Morgan Stanley
31
Morgan Stanley
New York
$1.71M -$781K -45,030 -29%
TA
32
Teachers Advisors
New York
$1.69M +$789K +45,493 +74%
Bank of America
33
Bank of America
North Carolina
$1.3M +$577K +33,270 +68%
USAA
34
United Services Automobile Association
Texas
$1.29M +$156K +9,000 +12%
State of Wisconsin Investment Board
35
State of Wisconsin Investment Board
Wisconsin
$1.12M +$175K +10,100 +17%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.09M +$298K +17,200 +33%
Fidelity Investments
37
Fidelity Investments
Massachusetts
$1.01M -$390K -22,501 -26%
TCIM
38
TIAA CREF Investment Management
New York
$1.01M +$111K +6,423 +11%
QI
39
QS Investors
New York
$996K – – –
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$934K +$137K +7,893 +15%
PPA
41
Parametric Portfolio Associates
Washington
$905K +$83K +4,787 +9%
QOP
42
Quinn Opportunity Partners
Virginia
$893K – – –
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$816K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$774K +$100K +5,785 +13%
MP
45
MFN Partners
Massachusetts
$725K – – –
Two Sigma Advisers
46
Two Sigma Advisers
New York
$571K +$628K +36,200 New
CSS
47
Cubist Systematic Strategies
Connecticut
$560K +$616K +35,511 New
OAM
48
Oxford Asset Management
United Kingdom
$555K -$66.7K -3,848 -10%
Barclays
49
Barclays
United Kingdom
$529K +$299K +17,260 +106%
TRSOTSOK
50
Teachers Retirement System of the State of Kentucky
Kentucky
$522K +$158K +9,101 +38%
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2019 in Review

112 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2019, worth a combined $656M — down 11% from $734M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RVNC positions and 9 closed out — a net gain of 11 holders — while 52 added to existing stakes and 14 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $24.8M. The largest seller was Millennium Management, cutting an estimated $6.25M.

  • 112 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2019, up from 101 in Q4 2018.
  • Funds reported $656M of Revance Therapeutics, Inc. stock for Q1 2019, down 11% quarter-over-quarter.
  • 20 funds opened new Revance Therapeutics, Inc. positions in Q1 2019 and 9 closed out, a net change of +11 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2019 was Wellington Management Group, an estimated $24.8M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2019 was Millennium Management, an estimated $6.25M sold.

Based on aggregated 13F filings for Q1 2019.